Torben Jorgensen New CEO at Biotage

As a part of this process, Torben Jorgensen will succeed Jeff Borkas the CEO of the company. For the last four years, Torben Jorgensenwas the CEO of Affibody. Prior to that, he held similar positions atthe Swedish biotech company Karo Bio, listed in Stockholm, and theDanish life science company DAKO, which annual turnover grew from DKK230 million to DKK 820 million during Torben Jorgensen's period as aCEO between 1990 and 1999. During this time, the global operatingresult rose from DKK 10 million to DKK 75 million.

Torben Jorgensen will enter his duties as CEO of Biotage inconjunction with the annual general assembly on 27 April.

"Torben Jorgensen will make a valuable contribution to Biotage,and we are convinced that he is the right person to lead the companyin the upcoming years when the focus will be on integration,optimization and organic growth", said Borje Ekholm, Chairman of theBoard of Biotage.

Jeff Bork will continue as a board member of Biotage, with aspecial focus on strategic issues. During his years as a chairman andCEO of the company, Jeff Bork carried through strategic acquisitionsand extensive cost reductions at Biotage, and lowered the consolidatedcosts in the businesses with SEK 400 million.

"Since taking on the position as the CEO of Biotage, Jeff Borkmade an tremendous effort to consolidate the businesses and make thecompany a market leader as a distributor of medical chemicallaboratories for synthesizing pharmaceutical substances. With Jeff asa board member, we can retain the continuity within the company and atthe same time make use of his solid business experience", said BorjeEkholm.

About Biotage

Biotage is a global company active in life science research withstrong technologies, a broad range of operations and a long-term viewof the market. The company offers solutions, knowledge and experiencein the areas of genetic analysis and medicinal chemistry. In 2005operations and products were acquired from the American companyArgonaut, further strengthening the medicinal chemistry product range.The customers include the world's top 30 pharmaceutical companies, theworld's top 20 biotech companies, and leading academic institutes. Thecompany is headquartered in Uppsala and has offices in the U.S.,Japan, UK, Germany and several other European countries. Biotage has330 employees and had sales of 430 MSEK in 2005. Biotage is listed onthe Stockholm stock exchange. Website: www.biotage.com

This information was brought to you by Waymakerhttp://www.waymaker.net